[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"coronary-artery-disease-cad\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:coronary-artery-disease-cad":26},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,54,0,25,[9,45,93,119,145,171,198,230,261,287,315,349,375,400,426,441,466,501,527,563,596,623,645,673,704],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100492944","coroflex-isar-neo-pmcf-study-100492944",false,"NCT05698732","Coroflex® ISAR NEO PMCF Study","Coroflex® ISAR NEO Coronary Stent System Post-Market Clinical Follow-up Study","rEPIC07","Inclusion Criteria:\n\nCoroflex® ISAR NEO is intended to be used for\n\n* Patients must be at least 18 years of age AND\n* The patient must fulfill the standard recommendations for Percutaneous Coronary Intervention (PCI) based on the last European Society of Cardiology (ESC) recommendations within his\u002F her regular treatment or that the use of the product has already been decided within the regular planning of the patient's treatment AND\n* Patients with Novo lesion length 2-4 mm AND\n* Informed consent signed\n\nExclusion Criteria:\n\n* Patients with express refusal by the patient to participate in the study.\n* Patients pregnant women and lactating women.\n* Patients with acute coronary syndrome (ACS) in a situation of cardiogenic shock (Killip 4).\n* Patients in whom anti-platelet and\u002For anti-coagulation therapy is contraindicated\n* Patients with lesions, that possibly can not be treated successfully with Percutaneous transluminal Coronary Angioplasty (PTCA) or stent implantation\n* Patients with known sensitivity to Sirolimus, the carrier Probucol, the procedural co-medication or the alloying component of the stent\n* Patients with known sensitivity to contrast agents who cannot be premedicated.\n* Patients with contraindications or hypersensitivity to sirolimus\n* Patients with a life expectancy of less than 2 years\n* Patients included in other clinical trials","ALL","18 Years",{"count":21,"type":22},3000,"ESTIMATED","OBSERVATIONAL","International, Multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Coroflex® ISAR NEO coronary stent system to meet EU Medical Device regulation (MDR) requirements in all the CONSECUTIVE patients treated with Coroflex® ISAR NEO coronary stent system sirolimus eluting stent.",[26,27],"Coronary Artery Disease (CAD)","Ischemic Heart Disease",[29,30,31],"MDR (Medical Device Regulations)","PMCF (Post-Market Clinical Follow-up)","Drug Eluting Stent","RECRUITING","2026-08-12",{"date":35,"type":36},"2026-08-14","ACTUAL",{"date":38,"type":36},"2023-08-04",{"date":40,"type":22},"2027-02-01",{"name":42,"class":43},"Fundación EPIC","OTHER",23,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":18,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":57,"conditions":58,"keywords":72,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":92},"100650085","health-for-hungary-h4h---longitudinal-collection-of-blood-samples-and-corresponding-data-100650085","NCT07743021","Health for Hungary (H4H) - Longitudinal Collection of Blood Samples and Corresponding Data","Health for Hungary - Longitudinal Collection of Blood Samples and Corresponding Data for Longterm Evaluation of Innovative Diagnostic Techniques in Subjects Without Clinically Relevant Disorders at Baseline to Institute Molecular Fingerprinting Reference Norms","H4H","Low- and Moderate-risk Cohort:\n\nInclusion Criteria:\n\n1. Signed informed consent form (ICF) of the study.\n2. Age \\> 40 years.\n3. Willingness to fill in the study questionnaire.\n4. No clinically relevant symptoms as assessed by the investigator, subjects with existing medical conditions may be eligible given that they are symptom free and that full treatment of the condition is medically confirmed.\n5. Willingness to participate in future visits.\n\nExclusion Criteria:\n\n1. Self-reported pregnancy (no test).\n2. Indications of clinically relevant medical conditions in self-reported healthy subjects.\n3. Self-reported symptom-free HIV, HCV and HBV infections. If HIV, HBV or HCV serology test is done and any of them are positive, the subject will be considered a screen failure.\n4. Any conditions preventing blood-draw.\n5. Vulnerable subjects.\n6. Foreseeable lack of compliance.\n7. Participation in another sample collection project of the same sponsor, in order to avoid double evaluation of the same subject.\n8. Participation (currently or in the past month) in an early phase clinical trial (phases I and II) involving testing of pharmaceutical products, if the last dose of pharmaceutical product administration was within 30 days of the first sample collection, and \u002F or further pharmaceutical product administration is planned.\n9. Vaccination within the last 14 days.\n\nHigh-risk Cohort:\n\nInclusion Criteria:\n\n1. Signed informed consent form (ICF) of the study.\n2. Age \\> 50 years.\n3. Willingness to fill in the study questionnaire.\n4. Willingness to participate in future visits and medical investigations, the presence of at least 2 of the following 3 risk factors (inclusion criteria #5-7):\n5. Hypertension, receiving antihypertensive treatment.\n6. Dyslipidemia\u002F Hypercholesterolemia (\\>5.2mmol\u002FL total cholesterol level), on or not on statin-treatment.\n7. Active or former smoker, with smoking history of at least 20 pack-years, and\u002For the presence of intermediate lung nodule on prior LDCT testing.\n8. No clinically relevant symptoms as assessed by the investigator; subjects with existing medical conditions may be eligible given that they are symptom free and that treatment of the condition is well documented.\n\nExclusion Criteria:\n\n1. Self-reported pregnancy (no test).\n2. Cardiovascular disease (including obstructive coronary artery disease, peripheral artery disease, aortic aneurysm) or other clinically significant heart disease (congenital, valvular heart disease, cardiomyopathy, heart failure and heart disease requiring ICD \\[implantable cardioverter defibrillator\\] or pacemaker therapy).\n3. Interstitial lung disease or severe COPD (chronic obstructive pulmonary disease) in GOLD stages 3 or 4.\n4. Active cancer or malignant disease with less than 5 years history of remission.\n5. Indications of clinically relevant medical conditions in self-reported healthy subjects, especially if (a) the condition requires regular or constant specialist checkups, or (b) pharmacological therapy indicates the presence of significant NCDs or multimorbidity, i.e., chronic polypharmacy (use of 5 or more medications at enrollment or over the last 6 months), or drug therapy necessitating a specialist input for initiation or management (e.g., combined anti-diabetic treatment with two or more medications).\n6. Self-reported symptom-free HIV, HCV and HBV infections. If HIV, HBV or HCV serology test is done and any of them are positive, the subject will be considered a screen failure.\n7. Any conditions preventing blood-draw or CT scans.\n8. Vulnerable subjects.\n9. Foreseeable lack of compliance.\n10. Participation in another sample collection project of the same sponsor, in order to avoid double evaluation of the same subject. 'High-risk' subjects enrolled in the low- and moderate-risk arm of the H4H study might be reallocated to the high-risk study arm after the first 4-5 visits.\n11. Participation (currently or in the past month) in an early phase clinical trial (phases I and II) involving testing of pharmaceutical products, if the last dose of pharmaceutical product administration was within 30 days of the first sample collection, and\u002For further pharmaceutical product administration is planned.\n12. Vaccination within the last 14 days of sample collection.",true,"40 Years",{"count":56,"type":22},15000,"The Health for Hungary (H4H) study collects blood samples and corresponding health data to investigate healthy aging and health-to-disease transitions in middle-aged and elderly participants.\n\nIndications Studied:\n\nApparently healthy, symptom-free participants are enrolled and followed up to study the onset of new-onset diseases with special emphasis on non-communicable diseases (NCDs).\n\nStudy Design:\n\nSingle-country, multicenter, prospective, longitudinal survey.\n\nObjectives:\n\nThe study aims to establish reference ranges of blood parameters using routine clinical blood tests and high-information-content methods, including proteomics, metabolomics and the so-called infrared molecular fingerprinting.\n\nThe study also aims to identify novel biomarkers of major non-communicable diseases, including atherosclerotic cardiovascular disease, cancer, diabetes and chronic respiratory disease.",[59,60,61,62,63,64,65,26,66,67,68,69,70,71],"Non-communicable Diseases (NCD)","Neoplams","Cancer","Lung Cancer (NSCLC)","Cardiovascular Diseases (CVD)","Atherosclerotic Cardiovascular Disease (ASCVD)","Peripheral Artery Disease (PAD)","Stroke (CVA) or TIA","Diabetes Mellitus (DM)","Type 2 Diabetes (T2DM)","Prediabetes","Chronic Respiratory Diseases","Chronic Obstructive Pulmonary Disease (COPD)",[73,74,75,76,77,78,79,80,81,82],"Personalized health","Molecular fingerprints","Longitudinal health monitoring","Early-stage disease detection","Innovative research platforms","Precision care","Proteomics","Metabolomics","in vitro diagnostics","Prevention medicine","2026-07-29",{"date":85,"type":36},"2026-08-03",{"date":87,"type":36},"2021-07-27",{"date":89,"type":22},"2030-12-31",{"name":91,"class":43},"Center for Molecular Fingerprinting Research Nonprofit LLC",33,{"id":94,"slug":95,"hasResults":12,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":102,"phases":103,"briefSummary":105,"conditions":106,"keywords":108,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":118},"100650073","clinical-study-of-coronary-extension-catheter-100650073","NCT07742345","Clinical Study of Coronary Extension Catheter","A Prospective, Multicenter, Single-Arm Clinical Study Evaluating the Safety and Efficacy of Coronary Extension Catheter in Percutaneous Coronary Intervention","Inclusion Criteria:\n\n* Age ≥18 years, regardless of gender;\n* Patients suitable for percutaneous coronary intervention (PCI) and for whom the use of an extension catheter is planned to assist the intervention;\n* Ability to understand the purpose of the study, willingness to voluntarily participate, and ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Reference vessel diameter \\\u003C 2 mm;\n* Presence of thrombus in the target vessel;\n* Unprotected left main coronary artery disease;\n* Acute myocardial infarction occurring within 7 days prior to enrollment;\n* Known intolerance to anticoagulant or antiplatelet therapy, or known allergy to contrast media;\n* Concurrent severe hepatic or renal disease, or other severe systemic conditions that render the patient unsuitable for PCI;\n* Pregnant or lactating women;\n* Currently participating in another clinical trial of a drug or medical device without having reached the primary endpoint or completed the trial;\n* Any other condition that, in the investigator's opinion, makes the patient ineligible for participation in this study.",{"count":101,"type":22},69,"INTERVENTIONAL",[104],"NA","This prospective, multicenter, single-arm study plans to enroll 69 subjects. Subjects meeting the protocol criteria will receive treatment with coronary extension catheters. The safety and efficacy of these catheters in percutaneous coronary intervention will be assessed through the collection and analysis of efficacy and safety endpoints during treatment and follow-up.",[26,107],"Percutaneous Coronary Intervention (PCI)",[107],"2026-07-28",{"date":85,"type":36},{"date":112,"type":36},"2026-06-25",{"date":114,"type":22},"2027-04-30",{"name":116,"class":117},"BrosMed Medical Co., Ltd","INDUSTRY",1,{"id":120,"slug":121,"hasResults":12,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":53,"sex":18,"minAge":19,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":102,"phases":129,"briefSummary":130,"conditions":131,"keywords":134,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":138,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":118},"100648553","the-effect-of-cardiac-rehabilitation-on-ferroptosis-in-patients-with-coronary-artery-disease-100648553","NCT07722637","The Effect of Cardiac Rehabilitation on Ferroptosis in Patients With Coronary Artery Disease","Evaluation of Ferroptosis-Related Biomarkers in Individuals With Coronary Artery Disease: The Impact of Cardiac Rehabilitation","Inclusion Criteria:\n\nPatients With Coronary Artery Disease (CAD):\n\n* Age between 18 and 75 years.\n* Diagnosis of coronary artery disease within the previous 3 months.\n* Eligible to participate in a cardiac rehabilitation program or voluntarily decline participation in the cardiac rehabilitation program.\n* Peak exercise capacity of ≥5 metabolic equivalents (METs).\n* Able to undergo cardiopulmonary exercise testing (CPET).\n* Able to understand the study procedures and provide written informed consent.\n\nHealthy Controls:\n\n* Age between 18 and 75 years.\n* No history of coronary artery disease or other cardiovascular diseases.\n* No history of chronic systemic diseases, including diabetes mellitus, hypertension, chronic kidney disease, chronic liver disease, inflammatory or autoimmune diseases, or malignancy.\n* Not receiving regular medication.\n* Able to provide written informed consent.\n\nExclusion Criteria:\n\nPatients With Coronary Artery Disease (CAD):\n\n* Decompensated heart failure.\n* Unstable angina pectoris.\n* Uncontrolled or complex ventricular arrhythmias.\n* Severe pulmonary hypertension.\n* Neurological, orthopedic, or musculoskeletal disorders limiting exercise performance.\n* Absolute contraindications to cardiopulmonary exercise testing or cardiac rehabilitation according to current clinical guidelines.\n* Chronic kidney failure or chronic liver disease.\n* Active infection.\n* Active inflammatory or autoimmune disease.\n* Active malignancy or history of malignancy.\n* Pregnancy.\n* Cognitive or psychiatric disorders that would interfere with study participation or protocol compliance.\n\nHealthy Controls:\n\n* History of coronary artery disease or other cardiovascular diseases.\n* History of chronic systemic diseases, including diabetes mellitus, hypertension, chronic kidney disease, chronic liver disease, inflammatory or autoimmune diseases, or malignancy.\n* Regular medication use within the previous 6 months.\n* Active infection.\n* Pregnancy.\n* Age younger than 18 years or older than 75 years.","75 Years",{"count":128,"type":22},90,[104],"Coronary artery disease (CAD) remains a major global health concern and is the leading cause of cardiovascular mortality worldwide. Cardiac rehabilitation (CR) is a comprehensive, evidence-based intervention that integrates exercise training with optimal medical management and has been shown to improve clinical outcomes in patients with CAD. The primary objective of this study is to investigate the effects of cardiac rehabilitation on ferroptosis, an iron-dependent form of regulated cell death, in patients with coronary artery disease.\n\nA total of 90 participants will be enrolled in the study after providing written informed consent. The study population will consist of three groups: 30 patients with CAD who participate in a cardiac rehabilitation program, 30 patients with CAD who voluntarily decline participation in cardiac rehabilitation, and 30 age- and sex-matched healthy volunteers without any known chronic disease. Peripheral venous blood samples will be collected from patients undergoing cardiac rehabilitation both before the initiation of the rehabilitation program and upon its completion. A single blood sample will be obtained from patients who decline participation in cardiac rehabilitation and from healthy control participants.\n\nTo evaluate ferroptosis-related molecular alterations, the expression levels of the ferroptosis-associated genes GPX4, SLC7A11, ACSL4, FSP1, NRF2, TFRC, and NCOA4 will be analyzed. In addition, serum concentrations of ferroptosis-related biomarkers, including free iron, 4-hydroxynonenal (4-HNE), malondialdehyde (MDA), and GPX4 protein, will be measured. The molecular and biochemical parameters will be compared among the three study groups, and changes in ferroptosis-related biomarkers before and after the cardiac rehabilitation program will be evaluated in patients undergoing cardiac rehabilitation.",[26,132,133],"Cardiac Rehab","Ferroptosis",[135,136,137],"cardiac rehabilitation","ferroptosis","Coronary artery disease",{"date":83,"type":36},{"date":140,"type":36},"2026-01-01",{"date":142,"type":22},"2026-11-15",{"name":144,"class":43},"TC Erciyes University",{"id":146,"slug":147,"hasResults":12,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":102,"phases":155,"briefSummary":157,"conditions":158,"keywords":4,"overallStatus":160,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":170},"100620442","phase-3-a-clinical-trial-to-investigate-the-effect-of-ea-230-on-hospital-length-of-stay-in-patients-with-coronary-artery-disease-cad-undergoing-coronary-artery-bypass-grafting-cabg-surgery-100620442","NCT07357675","A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery.","A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery.","EasyBoost","Inclusion Criteria:\n\n1. Patients aged ≥18 years, both male and female.\n2. Patients scheduled for elective on-pump CABG with at least 3 bypasses, with or without valve replacement.\n3. Willing and able to give written informed consent.\n\nExclusion Criteria:\n\n1. Patients undergoing non-elective on-pump CABG (i.e., emergency surgery). Emergency surgery is defined as planned surgery within 24 hours of diagnosis.\n2. Cardiogenic shock or hemodynamic instability that requires inotropes, vasopressors, or other mechanical devices, such as an intra-aortic balloon counter-pulsation (IABP), within 24 hours prior to surgery.\n3. Use of a left ventricular assist device (LVAD), or intra-aortic balloon pump or other cardiac devices, within 7 days prior to surgery.\n4. A requirement for any of the following within 7 days prior to surgery: defibrillator or permanent pacemaker, mechanical ventilation, IABP, LVAD, or other forms of mechanical circulatory support.\n5. Required cardiopulmonary resuscitation within 14 days prior to cardiac surgery.\n6. Known chronic liver disorder with Child-Pugh C classification.\n7. Confirmed or treated endocarditis requiring antimicrobial or antiviral treatment within 30 days prior to surgery or other current active infection requiring antimicrobial or antiviral treatment within 14 days prior to surgery.\n8. Ongoing sepsis (as defined by SEPSIS-3) within 2 weeks of screening or, in the opinion of the investigator, an untreated clinically significant infection (viral or bacterial) prior to or at Screening and before randomization.\n9. Immuno-compromised patients, as self-reported or as observed in medical records, including patients:\n\n   1. with solid organ transplantation.\n   2. known to be positive for human immunodeficiency virus (HIV).\n   3. that use immunosuppressive drugs or have received recent chemotherapy, at the discretion of the Investigator and including patients;\n\n   i. with active malignancy who have undergone chemotherapy within 30 days prior to trial entry.\n\n   ii. receiving chronic corticosteroid treatment equivalent to a prednisone dose of 10 mg or higher per day, within 30 days prior to trial entry, or an equivalent dose of another corticosteroid or any other anti-inflammatory or inflammation-suppressing medications such as interleukin blockers, methotrexate or similar therapies. Non-Steroidal Anti-Inflammatory Drugs are not exclusionary.\n10. Patients with hematological disorders (known disorders from myeloid and\u002For lymphoid origin, leucopenia (both active and in remission)).\n11. Known severe renal disease requiring dialysis, or a known estimated Glomerular Filtration Rate (eGFR) prior to admission of \\\u003C 20 ml\u002Fmin\u002F1.73 m2.\n12. Previous receipt of EA-230.\n13. Known hypersensitivity to the IMP.\n14. Use of any investigational drug within 1 month or 5 half-lives of said investigational drug (whichever is longer) prior to IMP administration in this trial. Participation in an observational clinical trial is not exclusionary.\n15. Women who are pregnant, breastfeeding or planning to become pregnant during the trial or within 28 days after IMP administration (WOCBP must have a negative pregnancy test prior to entry into the trial).\n16. Female patients of childbearing potential who are not willing\u002Fable to use adequate contraception and refrain from donating ova from enrolment and up to 28 days after IMP administration (contraceptive requirements are detailed in Annex 5. Contraceptive Guidance).\n17. Male patients who are not willing\u002Fable to use adequate contraception (if their partners is of childbearing potential) and refrain from donating sperm from enrolment and up to 28 days after IMP administration (contraceptive requirements are detailed in Annex 5. Contraceptive Guidance).\n18. Inability to personally provide written informed consent.\n19. Known or suspected of not being able to comply with the trial protocol, at the discretion of the Investigator.\n20. Any other condition which, in the Investigator's opinion, will interfere with completion of the trial.\n21. Being an employee of the Investigator or trial site with direct involvement in the proposed trial or other studies under the direction of that Investigator or trial site or being a family member of an employee of the Investigator with direct involvement in the proposed trial.",{"count":154,"type":22},300,[156],"PHASE3","EA-230 is a new therapy that may help people recover faster and have fewer problems after bypass surgery. In an earlier clinical trial, participants who received EA-230 during Coronary Artery Bypass surgery stayed in the Intensive Care Unit (ICU) and the hospital for a shorter time and had fewer serious complications, compared to those who received a placebo (an inactive therapy). The use of EA-230 was safe and well tolerated. This trial will test EA-230 in more participants to see if it really works and is safe to use in the future.\n\nThis is a Phase III trial. It will take place in multiple locations and will follow a double-blind, randomized, placebo-controlled clinical design, meaning neither doctors nor participants will know whether they receive EA-230 or placebo during the trial. Assignment to EA-230 or placebo occurs by chance, like throwing dice. The total duration of the trial, including medical check-ups, will be approximately 71 days. There is a total of 10 visits, including a screening-, a pre-operative-, and 2 remote visits. 7 of these visits are during your stay at the hospital.",[26,159],"Coronary Artery Bypass Graft Surgery(CABG)","NOT_YET_RECRUITING","2026-07-24",{"date":163,"type":36},"2026-07-27",{"date":165,"type":22},"2026-08-01",{"date":167,"type":22},"2027-07-01",{"name":169,"class":117},"EBI Anti Sepsis BV",6,{"id":172,"slug":173,"hasResults":12,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":102,"phases":181,"briefSummary":182,"conditions":183,"keywords":184,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":197},"100620864","basel-kosten-effektivitts-trial-drug-coated-balloon-dcb-vs-drug-eluting-stent-des-strategy-in-high-risk-patients-with-coronary-artery-disease-cad-100620864","NCT07363161","BASel Kosten-Effektivitäts-Trial: Drug-coated BALLoon (DCB) vs. Drug-eluting Stent (DES) Strategy in High-risk Patients With Coronary Artery Disease (CAD)","BASKET BALL - a Prospective, Multicenter, International, Open-label, Randomized Clinical Trial Comparing the Sirolimus-DCB Strategy vs. DES Strategy in de Novo High-risk Patients","BASKET BALL","Inclusion Criteria:\n\n* Subject must be 18 years of age or older\n* Subject can understand risks, benefits, and treatment alternatives of receiving DCB treatment or DES and provide written informed consent before any study-related procedure\n* Subject should have a documented angina pectoris or silent ischemia as assessed by non-invasive testing, or functional invasive assessment, or equivalent (dyspnea, arrhythmia, ≥75% diameter stenosis without stress test at staged procedure), or unstable angina, hemodynamically stable NSTEMI and STEMI more than 48 hours after primary PCI and without residual thrombotic material\n* Subject must be affiliated with a social security system, where applicable\n\nSubject must have at least one of the high clinical or anatomical risk features:\n\nHigh clinical risk, defined as:\n\n* DM on treatment (insulin or oral antidiabetic agents), or\n* At least 75 years of age, or\n* CKD (eGFR \\\u003C60 mL\u002Fmin\u002F1.73 m2), or\n* Treated for ACS (unstable angina, hemodynamically stable NSTEMI, hemodynamically stable STEMI more than 48 hours after uneventful primary PCI and without residual thrombotic material), or\n* High bleeding risk (defined by Academic Research Consortium criteria - ARC HBR)\n\nOR\n\nHigh anatomical risk lesions requiring treatment as follows:\n\n* Multivessel treatment (two or three vessels)\n* True bifurcation with side branch involvement\n* Long lesions (≥36 mm)\n* Lesion likely requiring calcium modification\n\nIn the case of multivessel (MV) disease, multiple vessels can be treated provided that all lesions are amenable to treatment with either DCB or DES and vessel size at the site of the lesion is \\>2.0 mm by visual assessment.\n\nThe trial does not restrict the number of target lesions. However, the operator should determine that all target lesions intended to be treated must be suitable for treatment with either DES or DCB. For patients randomized to the DCB arm, the likelihood of requiring provisional stenting must be assessed as less than 30% for each lesion requiring treatment.\n\nExclusion Criteria:\n\n* Primary PCI (acute STEMI patients)\n* Cardiogenic shock\n* Subject enrolled in an active interventional trial\n* Subject not able or unlikely to comply with the planned follow-ups\n* Subject who is pregnant, nursing or planning to become pregnant during the study\n* Subject not able to give informed consent\n* Subject under judicial protection, guardianship or curatorship or patient deprived of their liberty by judicial or administrative decision (where applicable)\n* Subject with a life expectancy \\\u003C12 months\n* Subjects with known allergies to antiplatelet agents (e.g., acetylsalicylic acid, P2Y12 inhibitors), anticoagulants (e.g., heparin, direct thrombin inhibitors), iodinated contrast media, or mTOR inhibitors (e.g., sirolimus and related compounds)\n* Angiographic exclusion criteria:\n\n  1. aorto-ostial lesions,\n  2. coronary bypass grafts requiring intervention,\n  3. chronic total occlusion requiring intervention\n  4. Previous PCI at any time of a vessel intended to be treated (Instent-restenosis lesions excluded)\n  5. Previous PCI within 30 days, except for recent STEMI, \\>48 hours after uneventful primary PCI and without residual thrombotic material on coronary angiography",{"count":180,"type":22},2184,[104],"The main objective of this randomized, multicenter, international, open-label clinical trial is to demonstrate that, in the context of percutaneous coronary intervention for complex coronary artery disease, a SeQuent® SCB interventional strategy is non-inferior to a new-generation\n\nDES strategy in terms of a 12- and 36-month composite of Target Vessel Failure (TVF), that includes:\n\n* cardiovascular death (CV death),\n* target vessel related MI (TV-MI),\n* clinically indicated target vessel revascularization (ci-TVR),\n* bleeding according to Bleeding Academic Research Consortium (BARC) Types 3-5.\n\nEligible subjects will be assigned in a 1:1 ratio to receive treatment of all lesions with either the SeQuent® SCB-based strategy or a DES-based strategy. The randomization will be performed prior to the index procedure once signed informed consent has been obtained and all eligibility criteria have been confirmed.\n\nAll Subjects will be followed for clinical outcomes at 3 months, 1, 2, and 3 years. A subset of 138 randomized patients will undergo control angiography after one-year clinical follow-up (+1 month). An independent core laboratory will analyze all baseline angiograms.\n\nIf, at 36 months, the non-inferiority of the SeQuent® SCB strategy compared to the DES strategy is achieved, superiority in terms of TVF and BARC Type 3-5 bleeding will be tested.\n\nAn optional extension of follow-up to 6 years may be implemented based on interim results and the joint decision of the Steering Committee and the Sponsor. Details regarding this optional extension are provided in the Clinical Investigation Plan.",[26],[185,186,187],"CAD","SCB","SeQuent® SCB","2026-07-17",{"date":190,"type":36},"2026-07-20",{"date":192,"type":36},"2026-06-17",{"date":194,"type":22},"2031-03",{"name":196,"class":117},"B. Braun Melsungen AG",3,{"id":199,"slug":200,"hasResults":12,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":102,"phases":208,"briefSummary":209,"conditions":210,"keywords":214,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":118},"100647570","expert-ivus-eye-vs-ivus-guided-left-main-bifurcation-pci-100647570","NCT07711106","\"Expert IVUS-Eye\" vs. IVUS-guided Left Main Bifurcation PCI","\"IVUS-Trained Eye\" vs. Intravascular Ultrasound in Left Main Bifurcation Stenting: A Prospective Randomized Trial","EYE-IVUS LM","Inclusion Criteria:\n\n* De novo lesion in an unprotected left main coronary artery, indicated for bifurcational stenting (provisional or 2-stent)\n* Patient referred for elective or delayed (non-emergency) stenting\n* Technical feasibility of performing IVUS\n* Signed informed consent\n\nExclusion Criteria:\n\n* ST-elevation myocardial infarction (STEMI) within the preceding 72 hours\n* Cardiogenic shock\n* Isolated (non-bifurcation) left main lesion\n* Prior PCI in the target segment\n* Diameter of one of the left main main branches \\\u003C 2 mm\n* Occlusion in the proximal segment of one of the main left main branches without the possibility of simultaneous recanalization\n* History of coronary artery bypass grafting (CABG)\n* Severe comorbidity with expected life expectancy \\\u003C 1 year\n* Participation in another interventional study\n* Patient is a woman who is pregnant or nursing;\n* Female patient of childbearing potential, i.e. who are not surgically sterile or post-menopausal (defined as no menses for 2 years without an alternative cause);\n* IVUS is strictly required for pre-PCI lesion severity assessment\n* Patients unable to tolerate, obtain or comply with dual antiplatelet therapy for at least 6 months in stable patients and 1 year in ACS patients;\n* Known contraindication or hypersensitivity to everolimus, platinum-chromium, or to anticoagulants.",{"count":207,"type":22},50,[104],"This is a prospective, randomized, controlled trial comparing two strategies for optimizing stent implantation during bifurcation stenting of the left main coronary artery (LM): an intravascular ultrasound (IVUS)-guided approach versus a \"IVUS-trained eye\" approach based on angiographic assessment and operator experience. All patients receive the same stent brand and procedure steps to minimize variability. The primary objective is to compare the planimetric stent appearance between two strategies.",[26,211,212,213],"Chronic Coronary Syndrome","Left Main Coronary Artery Disease","Coronary Bifurcation Lesion",[215,216,217,218,219,220,221],"Intravascular ultrasound","Percutaneous coronary intervention","Left main","Bifurcation","IVUS-trained eye","Stent optimization","Minimal stent area","2026-07-14",{"date":188,"type":36},{"date":225,"type":36},"2026-07-01",{"date":227,"type":22},"2027-12-31",{"name":229,"class":43},"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health",{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":237,"enrollmentInfo":238,"targetDuration":240,"studyType":23,"phases":4,"briefSummary":241,"conditions":242,"keywords":244,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":260},"100637316","crossover-vs-accurate-ostial-pci-for-medina-001-and-010-left-main-bifurcation-lesions-100637316","NCT07596706","Crossover vs Accurate Ostial PCI for Medina 0.0.1 and 0.1.0 Left Main Bifurcation Lesions","Crossover vs Accurate Ostial PCI for Medina 0.0.1 and 0.1.0 Left Main Bifurcation Lesions: the Multicenter OSTIAL-ANATOLIA Study","Inclusion Criteria:\n\n* Ostial left anterior descending artery or left circumflex artery disease\n* Coronary intervention with second or third generation drug-eluting stent\n\nExclusion Criteria:\n\n* Severe left main disease (≥30%, intravascular ultrasound plaque burden \\>50%)\n* History of coronary bypass grafting\n* Cardiogenic shock\n* Left main diameter greater than stent expansion capacity (for crossover group)\n* In-stent restenosis\n* End-stage liver or kidney disease (cirrhosis, hemodialysis-dependent chronic kidney disease),\n* Coronary intervention with bare-metal stent\n* Early discontinuation or inappropriate use of DAPT treatment\n* Patients lost to follow-up\n* Patient life expectancy \\\u003C1 year (such as cancer)","85 Years",{"count":239,"type":22},1000,"12 Months","Coronary artery disease is a leading cause of mortality and morbidity globally. The left coronary artery system is critically important due to its supply of a large area of myocardium. Ostia lesions of left anterior descending artery \\[LAD\\] and circumflex artery \\[CX\\]) present technical challenges during percutaneous coronary intervention (PCI) and are considered high-risk lesions due to their anatomical location, relationship with the left main coronary artery bifurcation. Two main approaches exist for treating these lesions: accurate ostial stenting and crossover stenting extending from the left main coronary artery to the relevant branch. Accurate ostial stenting aims to avoid unnecessary stenting of the left main coronary artery, while crossover stenting is more advantageous in terms of ensuring complete coverage of the ostial region. However, the crossover approach may have disadvantages such as larger stent implantation and potential side branch involvement. The current literature does not clearly define the clinical superiority of these two strategies. While various studies have shown no significant difference in mortality, myocardial infarction, and target lesion revascularization, the results are heterogeneous, and a definitive consensus has not been reached. The majority of current data are based on retrospective or observational studies. Therefore, well-designed prospective studies comparing crossover stenting and accurate ostial stenting strategies in the ostial left-sided coronary artery (LAD and CX) lesions are needed. This planned study aims to contribute to this gap in the literature by comparing the clinical outcomes of the two approaches.",[213,26,243],"Left Main Coronary Artery Stenosis",[245,246,247,248,249],"Ostial Lesion","Left anterior descending artery","Left circumflex artery","Crossover stenting","Accurate Ostial Stenting","2026-07-07",{"date":252,"type":36},"2026-07-09",{"date":254,"type":36},"2026-05-12",{"date":256,"type":22},"2027-09-15",{"name":258,"class":259},"Istanbul Mehmet Akif Ersoy Educational and Training Hospital","OTHER_GOV",2,{"id":262,"slug":263,"hasResults":12,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":267,"eligibilityCriteria":268,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":269,"enrollmentInfo":270,"targetDuration":4,"studyType":102,"phases":272,"briefSummary":273,"conditions":274,"keywords":275,"overallStatus":160,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":282,"completionDateStruct":283,"leadSponsor":285,"locationsCount":118},"100645150","micro-axial-flow-pump-supported-pci-in-complex-coronary-artery-disease-with-ischemic-lv-dysfunction-100645150","NCT07678021","Micro-axial Flow Pump-Supported PCI in Complex Coronary Artery Disease With Ischemic LV Dysfunction","Micro-axial Flow Pump-Supported PCI Plus Optimal Medical Therapy Versus Optimal Medical Therapy Alone in Complex Coronary Artery Disease With Ischemic LV Dysfunction: A Prospective, Multicenter, Randomized Controlled Trial","PIVOT","Inclusion Criteria:\n\n1. The subject is aged ≥18 years;\n2. The subject has been diagnosed with chronic or acute coronary syndrome and has a left ventricular ejection fraction \\\u003C35%;\n3. After comprehensive evaluation by the cardiac team, it is considered that the subject may benefit from PCI treatment;\n4. The subject has signed an informed consent form approved by the ethics committee, has good compliance after discharge, and is willing to undergo clinical follow-up.\n5. At least two vascular occlusive lesions (with the diameter of the occluded vessel \\>2.5mm) or unprotected left main coronary artery disease, and meeting one or more complex procedural criteria, or three-vessel disease, and meeting two or more complex procedural criteria;\n\nExclusion Criteria:\n\n1. Received mechanical circulatory assistance devices (including IABP, ECMO, Impella, etc.) before randomization;\n2. Acute myocardial infarction within 7 days or undergoing thrombolytic therapy;\n3. Combined with aortic dissection, pulmonary embolism, or severe pulmonary hypertension;\n4. Patients with cardiogenic shock or hemodynamic instability;\n5. Cardiopulmonary resuscitation was performed before randomization;\n6. Mechanical complications (including ventricular perforation, interventricular septal perforation, mitral valve chordae rupture, etc.) confirmed before randomization and subsequent to acute myocardial infarction;\n7. The mechanical circulatory assist device cannot be implanted or there are contraindications (including but not limited to left ventricular mural thrombus, artificial aortic valve or cardiac contractile device, moderate or severe aortic stenosis, moderate or severe aortic regurgitation, presence of stents in peripheral vascular access, tortuosity, dissection, and other severe vascular lesions that hinder the implantation of the investigational device, aortic aneurysm or severe malformation abnormalities, blood cell fragility or hemolytic blood system diseases, hypertrophic or hypertrophic obstructive cardiomyopathy, etc.);\n8. Severe abnormalities in platelets, with a count below 50×10\\^9\u002FL or above 600×10\\^9\u002FL;\n9. Active visceral hemorrhage or hemorrhagic stroke occurs within 1 month;\n10. Unable to use antiplatelet or anticoagulant drugs;\n11. Has a history of drug allergy and cannot tolerate conventional cardiovascular drug therapy and intraoperative medications;\n12. Severe renal insufficiency, requiring or expected to require long-term dialysis treatment;\n13. Severe active infection, puncture site infection, sepsis, or septicemia;\n14. Life expectancy is less than or equal to 1 year;\n15. Women who are pregnant or breastfeeding;\n16. Severe right heart failure or severe tricuspid regurgitation;\n17. Participation in other clinical trials has not yet reached the primary endpoint;\n18. Other situations that are unforeseen or deemed unsuitable by the researcher's comprehensive judgment.","80 Years",{"count":271,"type":22},452,[104],"Based on a multi-center randomized controlled study, this research aims to evaluate the efficacy and safety of interventional therapy supported by the CorVad percutaneous left ventricular assist system (Micro-axial Flow Pump） for patients with complex coronary heart disease (CHD) complicated by ischemic left ventricular systolic dysfunction. Through a prospective, multi-center, open-label 1:1 randomized controlled trial, a total of 452 patients with severe ischemic systolic dysfunction and complex coronary lesions were enrolled. The study compared the 12-month incidence of Major Adverse Cardiovascular and Cerebrovascular Events (MACCE) between patients who received interventional therapy supported by the CorVad percutaneous left ventricular assist system in addition to the most appropriate medical therapy and those who only received the most appropriate medical therapy. This was done to test whether the interventional therapy supported by the CorVad percutaneous left ventricular assist system can improve the prognosis of patients with severe ischemic systolic dysfunction and complex coronary lesions.",[26],[276,277,278,279],"Left ventricular assist system","complex coronary heart disease","left ventricular dysfunction","randomized controlled study","2026-06-28",{"date":225,"type":36},{"date":165,"type":22},{"date":284,"type":22},"2029-12-31",{"name":286,"class":259},"China National Center for Cardiovascular Diseases",{"id":288,"slug":289,"hasResults":12,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":293,"eligibilityCriteria":294,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":295,"enrollmentInfo":296,"targetDuration":4,"studyType":102,"phases":298,"briefSummary":299,"conditions":300,"keywords":301,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":118},"100641354","mind-body-interventions-in-coronary-artery-disease-100641354","NCT07633132","Mind-Body Interventions in Coronary Artery Disease","Effects of Combined Mind-Body Interventions in Patients With Coronary Artery Disease","MBI-CAD","Inclusion Criteria:\n\n* Diagnosed with stable coronary artery disease\n* Aged between 18 and 65 years\n* Able to read and understand Turkish\n* Able to complete study questionnaires and assessments\n* Willing to provide written informed consent\n\nExclusion Criteria:\n\n* History of acute coronary syndrome within the last 3 months\n* Presence of a diagnosed severe psychiatric disorder\n* Cognitive impairment or communication difficulties that may interfere with study participation\n* Previous regular participation in mind-body interventions such as progressive muscle relaxation, guided imagery, meditation, or similar programs","65 Years",{"count":297,"type":22},40,[104],"This randomized controlled study aims to evaluate the effects of a combined mind-body intervention consisting of progressive muscle relaxation and guided imagery on psychological outcomes in patients with stable coronary artery disease.\n\nA total of 40 participants will be randomly assigned to either an intervention group or a control group. The intervention group will receive eight individualized sessions over four weeks in addition to standard medical care, while the control group will continue with standard care only.\n\nPrimary and secondary outcomes will be assessed using validated self-report instruments, including the Perceived Stress Scale (PSS), Hospital Anxiety and Depression Scale (HADS), and COPE Inventory, administered at baseline and after the intervention period.\n\nThe main objective of the study is to determine whether structured mind-body techniques can reduce perceived stress, anxiety, and depressive symptoms and improve coping strategies in patients with coronary artery disease.",[26],[302,303,304,305],"Anxiety","Depression","Stress","Cardiac Rehabilitation","2026-06-18",{"date":308,"type":36},"2026-06-22",{"date":310,"type":36},"2026-06-09",{"date":312,"type":22},"2026-09",{"name":314,"class":43},"şeyda candeniz",{"id":316,"slug":317,"hasResults":12,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":321,"eligibilityCriteria":322,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":323,"targetDuration":4,"studyType":102,"phases":324,"briefSummary":325,"conditions":326,"keywords":338,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":118},"100638424","ecardiacrehab---a-hybrid-patient-centered-ehealth-programme-100638424","NCT07590635","eCardiacRehab - a Hybrid Patient-Centered eHealth Programme","eCardiacRehab - a Randomized Controlled Trial on a Hybrid Home-Based Patient-Centered eHealth Programme With Tailored Solutions","eCardiacRehab","Inclusion Criteria:\n\n* Adult Norwegian (or Scandinavian) speaking patients (≥ 18 years) who have a Norwegian national identification number\n* With coronary artery disease after percutaneous coronary intervention\n* Living at home\n* Have internet available\n* Provide signed informed consent\n\nExclusion Criteria:\n\n* Patients with cognitive impairment that may interfere with the ability to comply with the study protocol\n* Severe aortic stenosis\n* Severe arrhythmias\n* Expected lifetime less than one year as determined by study personnel\n* Otherwise clinically unstable\n* Not fully revascularized\n* Awaits percutaneous coronary intervention or coronary artery bypass graft surgery\n* Inability to comply with the study protocol due to any physical disability, somatic disease, or mental problems as determined by study personnel",{"count":239,"type":22},[104],"The overall aim of eCardiacRehab trial is to meet rehabilitation needs of patients with coronary artery disease (CAD) regardless of their access to traditional place-based rehabilitation by developing and evaluating the efficacy and cost effectiveness of an interdisciplinary and comprehensive home-based hybrid programme. eCardiacRehab address patient- and system level challenges to increase access to cardiac rehabilitation (CR). We give particular attention to older patients, women, and those with comorbidities or mental health challenges. The vision of the hybrid home-based eCardiacRehab programme is to make CR available to all.\n\neCardiacRehab is a prospective, multicentre randomized open-label blinded end point evaluation (PROBE) trial. The primary endpoint is a hierarchical composite endpoint using a win-ratio framework combining cardiovascular (CV) death, unplanned contacts to the Emergency Department (ED) for observation or admission (\\>24 hours) for CV disease, and quality of life. Inclusion criteria are adult Scandinavian speaking patients (≥ 18 years) who have a Norwegian national identification number, with CAD treated with Percutaneous Coronary Intervention (PCI), are living at home, and have internet available to them and providing signed informed consent. Exclusion criteria are patients with severe aortic stenosis, severe arrhythmias, expected lifetime less than one year as determined by study personnel, otherwise clinically unstable, not fully revascularized, awaits PCI or coronary artery bypass graft operation (CABG) or inability to comply with the study protocol due to any physical disability, somatic disease, cognitive impairment or mental health challenges as determined by study personnel.",[327,328,329,330,331,332,333,334,335,336,305,337,26],"Comorbidities and Coexisting Conditions","Ethics","Continuity of Patient Care","Older Adults (65 Years and Older)","Cost-Benefit Analysis","Adherence, Medication","Secondary Prevention of Coronary Heart Disease","Health Literacy","eHealth Literacy","Mental Health","Womens's Health",[305,339,340],"Coronary Artery Disease","Percutaneous Coronary Intervention",{"date":342,"type":36},"2026-06-23",{"date":344,"type":36},"2026-05-21",{"date":346,"type":22},"2037-12-31",{"name":348,"class":43},"Haukeland University Hospital",{"id":350,"slug":351,"hasResults":12,"nctId":352,"briefTitle":353,"officialTitle":354,"acronym":355,"eligibilityCriteria":356,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":357,"enrollmentInfo":358,"targetDuration":4,"studyType":102,"phases":360,"briefSummary":361,"conditions":362,"keywords":364,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":374,"locationsCount":118},"100641370","effect-of-mobile-based-home-cardiac-rehabilitation-on-coronary-plaque-100641370","NCT07660419","Effect of Mobile-Based Home Cardiac Rehabilitation on Coronary Plaque","Effect of Mobile Internet Technology-Based Home Cardiac Rehabilitation on Coronary Artery Plaque in Patients With Mild to Moderate Stenosis","MHCRT","Inclusion Criteria:\n\n* 1.Diagnosis of mild-to-moderate coronary artery stenosis: presence of plaque in any coronary artery causing mild (\\\u003C50%) or moderate (50%-69%) luminal stenosis.\n\n  2.Age between 18 and 70 years. 3.Asymptomatic during exercise or recovery phases of cardiopulmonary assessment, including absence of angina, ST-segment depression, or complex arrhythmias at rest or during exercise.\n\n  4.Normal troponin levels. 5.Provided signed informed consent.\n\nExclusion Criteria:\n\n* 1\\. Severe coronary artery stenosis. 2.Presence of severe respiratory or cardiovascular diseases (e.g., acute myocardial infarction, acute tachyarrhythmia, pulmonary edema, severe aortic stenosis).\n\n  3.Angina symptoms or signs during low-intensity exercise (\\\u003C5 METs) or recovery. 4.Complex arrhythmias at rest or during exercise. 5.Hemodynamic abnormalities during exercise (e.g., failure of systolic blood pressure or heart rate to increase, or a decrease in blood pressure with increased exercise workload).\n\n  6.Severe psychological disorders. 7.Left ventricular ejection fraction (LVEF) \\\u003C 40%. 8.Elevated troponin levels. 9.Inability to undergo cardiopulmonary exercise testing due to neuromuscular or musculoskeletal disorders.\n\n  10.Presence of other severe comorbidities. 11.Refusal to sign informed consent.","70 Years",{"count":359,"type":22},176,[104],"This single-center, randomized controlled trial aims to evaluate the efficacy of a mobile internet-based, home-based cardiac rehabilitation program in patients with mild to moderate coronary artery stenosis. A total of 176 eligible participants will be randomized to receive either a personalized lifestyle intervention via a mobile platform or routine clinical care. The primary endpoint is the change in non-calcified coronary plaque volume, as measured by coronary computed tomography angiography (CTA) at 12 months. Participants will be followed for a total of 36 months to comprehensively assess the long-term impact of this digital lifestyle intervention on plaque progression and cardiovascular outcomes.",[26,363],"Coronary Stenosis",[26,365,366,363,367,368],"Home-based Cardiac Rehabilitation","Mobile Health (mHealth)","Non-calcified Plaque","Coronary Computed Tomography Angiography (CCTA)","2026-06-16",{"date":308,"type":36},{"date":372,"type":36},"2024-12-31",{"date":227,"type":22},{"name":286,"class":259},{"id":376,"slug":377,"hasResults":12,"nctId":378,"briefTitle":379,"officialTitle":379,"acronym":4,"eligibilityCriteria":380,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":381,"targetDuration":4,"studyType":102,"phases":382,"briefSummary":383,"conditions":384,"keywords":387,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":393,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":118},"100642433","effects-of-myofascial-release-on-cardiac-patients-after-median-sternotomy-100642433","NCT07649330","Effects of Myofascial Release on Cardiac Patients After Median Sternotomy","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Able to communicate verbally and follow instructions\n* Diagnosed by a physician with coronary artery disease, valvular disease, or aortic disease\n* Undergoing median sternotomy\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Presence of a cardiac pacemaker\n* Presence of a ventricular assist device (VAD)\n* Existing central nervous system disorders (e.g., hemorrhagic or ischemic stroke, spinal cord injury, traumatic brain injury)\n* Cognitive impairment or inability to understand\u002Ffollow instructions\n* Diagnosed with chronic obstructive pulmonary disease (COPD)\n* History of previous thoracic surgery\n* ICU stay longer than 14 days",{"count":207,"type":22},[104],"After deciding to join this study and signing the informed consent form, participants will undergo the following interventions:\n\nAll participants will receive a preoperative assessment (Tp) before surgery. Within five days after transferring from the ICU to the general ward, participants will receive a baseline assessment (T0). After completing seven sessions of myofascial release (MFR), a post-intervention assessment (T1) will be conducted.\n\nAssessments include maximum inspiratory pressure (MIP), maximum expiratory pressure (MEP), pulmonary function tests, mid- and lower-thoracic mobility, surface electromyography (sEMG) to measure diaphragmatic and sternocleidomastoid muscle activity, and pain scores. Pulmonary function tests include forced vital capacity (FVC), forced expiratory volume in one second (FEV1), FEV1\u002FFVC ratio, and maximum voluntary ventilation (MVV).\n\nParticipants will be randomly assigned to an intervention group or a control group. The intervention group will receive myofascial release therapy in addition to routine physical therapy in the general ward. Routine therapy includes daily physical therapy sessions such as out-of-bed activities, incentive spirometry training (Triflow), and functional exercises. The MFR intervention consists of three steps:\n\nThe therapist places both hands on the thoracic outlet, with the index and middle fingers above the clavicle.\n\nOne hand is placed on the anterior chest and the other hand parallel on the participant's back.\n\nBoth hands are placed on the anterolateral region of the thoracoabdominal diaphragm.\n\nDuring each step, participants are instructed to take 10 slow, deep breaths and direct airflow toward the therapist's hands. Each session lasts approximately 15 minutes, once daily, for seven sessions.\n\nThe control group will receive only routine physical therapy (out-of-bed activities, incentive spirometry, and functional exercises) without additional myofascial release therapy.",[385,26,386],"Aortic Aneurysm and Dissection","Valve Heart Disease",[388,389,339,390,391,392],"Median Sternotomy","Cardiac Surgery","Aortic Aneurysm","Aortic Dissection","Valvular Heart Disease",{"date":369,"type":36},{"date":395,"type":36},"2026-03-25",{"date":397,"type":22},"2027-09",{"name":399,"class":43},"Siou-Pin Huang",{"id":401,"slug":402,"hasResults":12,"nctId":403,"briefTitle":404,"officialTitle":404,"acronym":4,"eligibilityCriteria":405,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":406,"targetDuration":4,"studyType":102,"phases":407,"briefSummary":408,"conditions":409,"keywords":412,"overallStatus":160,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":118},"100640646","effects-of-royal-jelly-and-propolis-on-metabolomic-signatures-inflammation-and-cardiovascular-risk-in-patients-with-coronary-artery-disease-100640646","NCT07596992","Effects of Royal Jelly and Propolis on Metabolomic Signatures, Inflammation, and Cardiovascular Risk in Patients With Coronary Artery Disease.","Inclusion Criteria:\n\n* Both sexes\n* Over 18 years of age;\n* Diagnosed with Coronary Artery Disease: confirmed by coronary angiography, coronary computed tomography angiography, or functional testing with ischemic load);\n* Participants who are asymptomatic or have angina limited to functional class III will be considered;\n* Patients who have already undergone coronary revascularization and angioplasty may participate;\n* the last acute coronary event must have occurred more than one year ago.\n\nExclusion Criteria:\n\n* Unstable Coronary Artery Disease;\n* Pre-operative coronary artery bypass grafting or awaiting elective angioplasty;\n* Unstable angina;\n* NYHA functional class III or higher;\n* Advanced chronic kidney disease (creatinine clearance \\\u003C 30 ml\u002Fmin\u002F1.73 m²);\n* Individuals with autoimmune diseases.",{"count":207,"type":22},[104],"The aim of this project is to evaluate the effect of bioactive compound sources, propolis and royal jelly, on metabolomics, inflammation, and cardiovascular risk markers in participants with coronary artery disease. A longitudinal double-blind randomized clinical trial will be carried out, involving CAD participants for two months.",[26,410,411],"Oxidative Stress","Inflammation",[413,414,415,416,417],"royal jelly","propolis","coronary artery disease","oxidative stress","inflammation",{"date":419,"type":36},"2026-05-19",{"date":421,"type":22},"2026-05-18",{"date":423,"type":22},"2028-12",{"name":425,"class":43},"Universidade Federal Fluminense",{"id":427,"slug":428,"hasResults":12,"nctId":429,"briefTitle":430,"officialTitle":430,"acronym":4,"eligibilityCriteria":405,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":431,"targetDuration":4,"studyType":102,"phases":432,"briefSummary":433,"conditions":434,"keywords":435,"overallStatus":160,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":437,"startDateStruct":438,"completionDateStruct":439,"leadSponsor":440,"locationsCount":118},"100640154","ginger-in-the-modulation-of-inflammatory-cytokines-and-oxidative-stress-in-patients-with-coronary-artery-disease-100640154","NCT07596979","Ginger in the Modulation of Inflammatory Cytokines and Oxidative Stress in Patients With Coronary Artery Disease",{"count":207,"type":22},[104],"The study aims to evaluate the effect of ginger supplementation on inflammatory cytokines and markers of oxidative stress in patients with Coronary Artery Disease (CAD). A longitudinal double-blind randomized clinical trial will be carried out, involving CAD participants for two months.",[26,410,411],[436,415,417,416],"ginger",{"date":419,"type":36},{"date":421,"type":22},{"date":423,"type":22},{"name":425,"class":43},{"id":442,"slug":443,"hasResults":12,"nctId":444,"briefTitle":445,"officialTitle":446,"acronym":447,"eligibilityCriteria":448,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":449,"targetDuration":451,"studyType":23,"phases":4,"briefSummary":452,"conditions":453,"keywords":454,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":459,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":464,"locationsCount":118},"100636447","bern-intracoronary-optical-coherence-tomography-and-coronary-computed-tomography-angiography-registry-100636447","NCT07565805","Bern Intracoronary Optical Coherence Tomography and Coronary Computed Tomography Angiography Registry","Bern Intarcoronary Optical Coherence Tomography and Coronary Computed Tomography Angiography Registry","BIOCORE","Inclusion Criteria:\n\n1. ≥18 years of age\n2. Written informed consent\n3. CCTA within 3 months from invasive coronary angiography and OCT\n4. At least one vessel with ≥50% diameter stenosis on CCTA\n5. OCT performed in native coronary arteries (i.e. pre-PCI or no PCI)\n\nExclusion Criteria:\n\n1. CCTA performed more than 3 months from OCT\n2. Poor OCT quality\n3. Poor CCTA quality\n4. Coronary anomalies\n5. Prior PCI or CABG in the vessel imaged with OCT",{"count":450,"type":22},816,"5 Years","Bern Intracoronary Optical Coherence Tomography and Coronary Computed Tomography Angiography Registry (BIOCORE) is a systematic institutional registry on patients undergoing paired CCTA and OCT for validation and development of advanced methods to determine coronary plaque morphology, lesion severity, PCI guidance, and it association with long-term clinical outcomes.",[26],[455,456,457],"Coronary artery disease (CAD)","Optical coherence tomography (OCT)","Coronary computed tomography angiography (CCTA)","2026-05-07",{"date":254,"type":36},{"date":461,"type":36},"2025-10-17",{"date":463,"type":22},"2033-12-31",{"name":465,"class":43},"Insel Gruppe AG, University Hospital Bern",{"id":467,"slug":468,"hasResults":12,"nctId":469,"briefTitle":470,"officialTitle":471,"acronym":472,"eligibilityCriteria":473,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":474,"targetDuration":4,"studyType":102,"phases":476,"briefSummary":477,"conditions":478,"keywords":485,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":494,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":499,"locationsCount":118},"100613651","surgical-versus-percutaneous-revascularization-in-patients-with-reduced-left-ventricular-function-stich-30-nl-100613651","NCT07269366","Surgical Versus Percutaneous Revascularization in Patients With Reduced Left Ventricular Function (STICH 3.0-NL)","Surgical Versus Percutaneous Revascularization in Patients With Reduced Left Ventricular Function","STICH 3*0-NL","Inclusion Criteria:\n\n* Age ≥ 18 years\n* LVEF≤ 40%\n* Angina pectoris, CCS≥2 and\u002For hospitalization for ACS or heart failure within 1 year prior to randomization\n* Multivessel CAD (2-3 vessel-disease with coronary lesions \\>70% and involvement of proximal LAD, and\u002For LM stenosis of \\>50%). Target vessels are determined by the local Heart Time\n* Clinical and angiographical characteristics suitable for isolated coronary revascularization both by CABG or PCI according to the judgment of the local Heart Team\n* Written informed consent\n\nExclusion Criteria:\n\n* ACS \\\u003C 48 hours before randomization\n* Valvular\u002Fstructural heart disease requiring intervention\n* Contra-indications to DAPT\n* Non-cardiac condition with life expectancy \\\u003C 1 year\n* Previous CABG\n* Decompensated HF at the time of inclusion",{"count":475,"type":22},358,[104],"This randomized multicenter trial compares coronary artery bypass grafting (CABG) with percutaneous coronary intervention (PCI) in 358 patients with ischemic left ventricular dysfunction and multivessel coronary disease. The study evaluates differences in survival, major cardiovascular events, and quality of life over 4 years, and contributes to the international STICH 3.0 collaboration assessing long-term outcomes.",[339,26,479,480,481,482,483,484],"Multivessel Coronary Artery Disease","CABG","CABG in Low EF","Heart Failure","PCI","Revascularization",[486,415,487,488,489,490,491,492,493],"coronary artery","heart failure","low ejection fraction","hfref","cabg","coronary artery bypass graft","pci","revascularization",{"date":254,"type":36},{"date":496,"type":22},"2026-05",{"date":498,"type":22},"2034-05",{"name":500,"class":43},"University Medical Center Groningen",{"id":502,"slug":503,"hasResults":12,"nctId":504,"briefTitle":505,"officialTitle":506,"acronym":507,"eligibilityCriteria":508,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":509,"targetDuration":511,"studyType":23,"phases":4,"briefSummary":512,"conditions":513,"keywords":515,"overallStatus":160,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":519,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":525,"locationsCount":118},"100640922","coronary-artery-disease-screening-in-patients-with-chronic-kidney-disease-100640922","NCT07585695","Coronary Artery Disease Screening in Patients With Chronic Kidney Disease","Screening for Coronary Artery Disease in Patients With Chronic Kidney Disease","EVACKD","Inclusion Criteria:\n\n* Male or female patients aged over 18 years\n* Affiliated with the French social security system\n* Patients at renal risk based on albuminuria (Alb) and glomerular filtration rate (GFR \\\u003C 30 mL\u002Fmin\u002F1.73 m², or GFR \\\u003C 45 mL\u002Fmin\u002F1.73 m² with albuminuria \\> 30 mg\u002Fg, or GFR \\\u003C 60 mL\u002Fmin\u002F1.73 m² with albuminuria \\> 300 mg\u002Fg)\n* Patients undergoing, independently of the research and according to the clinician's decision as part of standard care, CZT-SPECT myocardial perfusion imaging with coronary flow reserve measurement for cardiovascular risk assessment\n* Having expressed no objection to participation in this study\n\nExclusion Criteria:\n\n* Legally protected adult (Article L1121-8 of the French Public Health Code)\n* Person deprived of liberty (Article L1121-8 of the French Public Health Code)\n* Pregnant woman\n* Patient who has undergone a normal coronary exploration within the past year",{"count":510,"type":22},283,"25 Months","Patients with chronic kidney disease (CKD) have a markedly increased cardiovascular risk, with coronary artery disease being a leading cause of morbidity and mortality. Conventional cardiovascular risk scores and non-invasive diagnostic tests have limited accuracy in this population, partly due to atypical symptoms and frequent structural heart disease. Coronary flow reserve (CFR) is a key marker of coronary microvascular dysfunction and has strong prognostic value, but its assessment is usually limited to invasive techniques. Recent advances in cadmium-zinc-telluride single-photon emission computed tomography (CZT-SPECT) allow non-invasive measurement of CFR. The EVACKD study aims to evaluate the prognostic value of CFR assessed by CZT-SPECT in patients with CKD for predicting major adverse cardiovascular events over a 2-year follow-up.",[514,26],"Chronic Kidney Disease (CKD)",[516,517,415],"Chronic Kidney Disease","Coronary Flow Reserve","2026-05-06",{"date":520,"type":36},"2026-05-14",{"date":522,"type":22},"2026-06-01",{"date":524,"type":22},"2028-01-31",{"name":526,"class":43},"University Hospital, Grenoble",{"id":528,"slug":529,"hasResults":12,"nctId":530,"briefTitle":531,"officialTitle":532,"acronym":533,"eligibilityCriteria":534,"healthyVolunteers":53,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":535,"targetDuration":451,"studyType":23,"phases":4,"briefSummary":537,"conditions":538,"keywords":545,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":561,"locationsCount":118},"100637404","ai-assisted-ct-for-risk-stratification-in-coronary-artery-disease-action-100637404","NCT07577609","AI-assisted CT for Risk Stratification in Coronary Artery Disease (ACTION)","Artificial Intelligence-assisted CT for Risk Stratification in COronary Artery Disease to PreveNt Future Coronary Events and Improve Outcomes","ACTION","Inclusion Criteria:\n\n* Adults aged ≥18 years\n* Undergoing clinically indicated cardiac CT\n* Able and willing to provide informed consent\n\nExclusion Criteria:\n\n* History of malignancy\n* Abnormal renal function (e.g., eGFR or serum creatinine outside reference range)\n* Contraindications to iodinated contrast agents or CT imaging",{"count":536,"type":22},10000,"The goal of this observational study is to learn if AI-assisted cardiac CT imaging can improve cardiovascular risk stratification and prediction of future coronary events in an adult population undergoing clinically indicated cardiac CT.\n\nThe main questions it aims to answer are:\n\n* Can AI-enhanced cardiac CT accurately assess cardiovascular risk in a real-world adult population?\n* How do CT-derived plaque characteristics correlate with clinical, biochemical, and lifestyle risk factors? Researchers will compare subgroups (e.g., patients with different risk profiles, biomarkers, or imaging findings, and a subset undergoing OCT imaging) to see if differences in imaging and clinical parameters are associated with cardiovascular risk and plaque vulnerability.\n\nParticipants will:\n\n* Provide informed consent and medical history\u002Fdemographic information\n* Undergo blood sampling for cardiovascular and metabolic biomarkers\n* Have a resting ECG performed\n* Complete a detailed lifestyle and health questionnaire\n* Receive a non-invasive cardiac CT scan interpreted by an expert\n* Potentially receive heart rate-lowering medication (e.g., metoprolol) if required for imaging quality\n* Be referred for further clinical evaluation if clinically indicated ",[26,539,540,541,542,543,544],"Computed Tomography Angiography","Biomarkers","AI (Artificial Intelligence)","Lipoprotein(a)","Atheroscleroses, Coronary","Myocardial Ischemia",[546,547,548,549,550,551,552,553],"AI-assisted cardiac CT","Coronary CT angiography (CCTA)","Cardiovascular risk stratification","Coronary plaque characterization","High-risk plaque","Machine learning","CT-FFR (fractional flow reserve)","Coronary calcium scoring","2026-05-05",{"date":556,"type":36},"2026-05-11",{"date":558,"type":36},"2022-12-21",{"date":560,"type":22},"2032-12-21",{"name":562,"class":43},"University of Galway",{"id":564,"slug":565,"hasResults":12,"nctId":566,"briefTitle":567,"officialTitle":567,"acronym":568,"eligibilityCriteria":569,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":570,"targetDuration":451,"studyType":23,"phases":4,"briefSummary":571,"conditions":572,"keywords":578,"overallStatus":160,"whyStopped":4,"lastUpdateSubmitDate":588,"lastUpdatePostDateStruct":589,"startDateStruct":590,"completionDateStruct":592,"leadSponsor":594,"locationsCount":118},"100636493","overviewing-real-world-outcomes-to-boost-interventional-management-of-calcified-coronary-lesions-the-orobica-registry-100636493","NCT07566403","Overviewing Real-World Outcomes to Boost Interventional Management of CAlcified Coronary Lesions: the OROBICA Registry.","OROBICA","Inclusion Criteria:\n\n* Patients undergoing percutaneous coronary intervention (PCI) for severely calcified coronary lesions, angiographically defined as radiopacities noted without cardiac motion before contrast injection, generally involving both sides of the arterial wall.\n* Patients undergoing PCI for calcified coronary lesions with intracoronary optical coherence tomography (OCT) showing at least one of the following features:\n\n  * calcium arc ≥180°\n  * calcium thickness ≥0.3 mm\n  * calcium length ≥3 mm\n  * presence of calcified nodules\n* Patients undergoing PCI for calcified coronary lesions with intravascular ultrasound (IVUS) showing at least one of the following features:\n\n  * calcium arc ≥180°\n  * concentric or superficial calcium with extensive acoustic shadowing\n  * presence of calcified nodules\n\nExclusion Criteria:\n\n* Lack of availability of essential clinical or procedural data.\n* Refusal or withdrawal of informed consent for the prospective component of the registry, when applicable.\n* Exercise of the right to object to data processing, according to applicable data protection regulations.",{"count":21,"type":22},"The OROBICA (Overviewing Real-World Outcomes to Boost Interventional Management of CAlcified Coronary Lesions) Registry is a multicenter, ambispective, real-world observational study designed to evaluate clinical, procedural, imaging, and economic outcomes of patients undergoing percutaneous coronary intervention (PCI) for severely calcified coronary artery disease.\n\nCoronary artery calcification represents one of the main determinants of procedural complexity and adverse outcomes in contemporary interventional cardiology. Despite the increasing availability of advanced calcium-modification technologies and intracoronary imaging techniques, evidence regarding the optimal treatment strategy in real-world clinical practice remains limited, particularly among high-risk and complex patients often underrepresented in randomized trials.\n\nThe OROBICA Registry aims to systematically collect longitudinal data from all-comer patients treated for severely calcified coronary lesions using contemporary PCI strategies, including intracoronary imaging guidance (IVUS\u002FOCT), rotational atherectomy, orbital atherectomy, intravascular lithotripsy, specialty balloons, and combined calcium-modification approaches.\n\nThe primary objective is to assess clinical and procedural outcomes, with particular focus on target vessel failure (TVF). Secondary and exploratory objectives include evaluation of procedural success, imaging findings, predictors of adverse outcomes, healthcare resource utilization, and economic impact associated with the treatment of calcified coronary lesions.\n\nThe registry is designed as a flexible research platform intended to support future hypothesis-generating analyses and provide real-world evidence to improve personalized management strategies for calcified coronary artery disease.",[26,573,574,575,576,577,340],"Calcific Coronary Arteriosclerosis","Intravascular Lithotripsy; Rotational Atherectomy; OFDI","Orbital Atherectomy","Optical Coherence Tomography (OCT)","Intravascular Ultrasound",[579,415,580,581,582,583,584,585,586,587],"Coronary calcifications","percutaneous coronary intervention","intravascular imaging","atherectomy","intravascular lithotripsy","rotational atherectomy","orbital atherectomy","cutting balloon","target vessel failure","2026-05-04",{"date":518,"type":36},{"date":591,"type":22},"2026-06-30",{"date":593,"type":22},"2036-06-30",{"name":595,"class":43},"Papa Giovanni XXIII Hospital",{"id":597,"slug":598,"hasResults":12,"nctId":599,"briefTitle":600,"officialTitle":601,"acronym":4,"eligibilityCriteria":602,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":603,"targetDuration":4,"studyType":102,"phases":605,"briefSummary":606,"conditions":607,"keywords":612,"overallStatus":160,"whyStopped":4,"lastUpdateSubmitDate":615,"lastUpdatePostDateStruct":616,"startDateStruct":618,"completionDateStruct":619,"leadSponsor":621,"locationsCount":4},"100627470","comprehensive-invasive-physiological-evaluation-of-obstructive-coronary-artery-disease-100627470","NCT07449052","Comprehensive Invasive Physiological Evaluation of Obstructive Coronary Artery Disease","Inclusive Invasive Physiological Assessment in Angina Syndromes - Obstructive Coronary Artery Disease","Inclusion Criteria:\n\n* Patients \\>18 years of age\n* Hemodynamically relevant obstructive coronary artery disease (as assessed by pressure wire evaluation) in the left anterior descending coronary artery amenable to percutaneous coronary intervention at the discretion of the operator.\n\nExclusion Criteria:\n\n* Prior coronary artery bypass graft surgery.\n* Stenosis \\>90% in the target vessel or a stenosis deemed unsafe for pressure wire instrumentation\n* Known severe left ventricular dysfunction (left ventricular ejection fraction by any imaging modality)\n* Severe valvular disease\n* Renal impairment (estimated glomerular filtration rate \\\u003C30mL\u002Fmin)\n* Contra-indications for the use of adenosine or acetylcholine\n* Expected inability to conform to the clinical follow-up\n* Unable or unwilling to use the ORBITA-app\n* Life expectancy of less than 12 months.",{"count":604,"type":22},450,[104],"The goal of this clinical trial is to test whether adding coronary function testing and starting targeted medical treatment for identified vasomotor disorders will also improve angina symptoms and quality of life in patients with obstructive coronary artery disease who undergo percutaneous coronary intervention. The main question it aims to answer is:\n\nDoes performing coronary function testing in patients with obstructive coronary artery disease who undergo percutaneous coronary intervention lead to better relieve of angina symptoms and improvement in quality of life?\n\nResearchers will compare this group undergoing coronary function testing with a control group who will solely undergo percutaneous coronary intervention.\n\nParticipants will:\n\n* Undergo percutaneous coronary intervention and coronary function testing in the intervention arm\n* Undergo percutaneous coronary intervention in the control arm",[26,608,609,610,611],"Obstructive Coronary Artery Disease","Coronary Microvascular Dysfunction (CMD)","Vasospasm, Coronary","Stable Angina Pectoris",[613,340,614],"Coronary Function Testing","Stable Angina","2026-04-30",{"date":617,"type":36},"2026-05-01",{"date":617,"type":22},{"date":620,"type":22},"2029-03-01",{"name":622,"class":43},"UMC Utrecht",{"id":624,"slug":625,"hasResults":12,"nctId":626,"briefTitle":627,"officialTitle":628,"acronym":4,"eligibilityCriteria":629,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":126,"enrollmentInfo":630,"targetDuration":4,"studyType":102,"phases":632,"briefSummary":634,"conditions":635,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":637,"lastUpdatePostDateStruct":638,"startDateStruct":640,"completionDateStruct":642,"leadSponsor":643,"locationsCount":118},"100617402","phase-2-a-study-of-srsd107-in-participants-with-chronic-coronary-andor-peripheral-arterial-disease-100617402","NCT07318155","A Study of SRSD107 in Participants With Chronic Coronary and\u002For Peripheral Arterial Disease","A Phase 2a Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of Subcutaneously Administered SRSD107 in Participants With Chronic Coronary and\u002For Peripheral Arterial Disease","Inclusion Criteria:\n\n* Able to comprehend and willing to sign an ICF and to abide by the study restrictions.\n* Males or females aged 18 to 75 years, inclusive.\n* Body mass index (BMI) between 18.0 and 35.0 kg\u002Fm2, inclusive.\n* History of chronic coronary and\u002For peripheral arterial disease\n\nExclusion Criteria:\n\n* Known bleeding disorder\n* Severe heart failure with known left ventricular ejection fraction \\\u003C35%, or New York Heart Association (NYHA) class III or IV symptoms.\n* Genetic cardiomyopathies or other non-ischemic cardiomyopathies that are not related to atherosclerotic cardiovascular disease.\n* History of ethanol abuse or addictive drug use (cannabis products allowed) within 6 months of screening.\n* Receipt of an investigational drug (IP) within 30 days or 5 half-lives of that drug, whichever is longer, prior to dose administration in this study.\n* Previous use of SRSD107.",{"count":631,"type":22},104,[633],"PHASE2","The study is a Phase 2a, randomized, double-blind, placebo-controlled, sequential cohort study to evaluate the pharmacodynamics (PD), safety and pharmacokinetics (PK) of multiple doses of SRSD107 in participants with coronary arterial disease (CAD) and\u002For peripheral arterial disease (PAD) with aspirin as background concomitant therapy.",[26,636],"Peripheral Arterial Disease","2026-04-23",{"date":639,"type":36},"2026-04-29",{"date":641,"type":36},"2025-03-11",{"date":423,"type":22},{"name":644,"class":117},"Sirius Therapeutics Co., Ltd.",{"id":646,"slug":647,"hasResults":12,"nctId":648,"briefTitle":649,"officialTitle":650,"acronym":651,"eligibilityCriteria":652,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":269,"enrollmentInfo":653,"targetDuration":4,"studyType":102,"phases":655,"briefSummary":656,"conditions":657,"keywords":660,"overallStatus":160,"whyStopped":4,"lastUpdateSubmitDate":664,"lastUpdatePostDateStruct":665,"startDateStruct":667,"completionDateStruct":669,"leadSponsor":671,"locationsCount":4},"100635400","stenting-versus-drug-eluting-balloons-only-in-treatment-of-coronary-bifurcation-lesion-robust-study-100635400","NCT07552194","Stenting Versus Drug Eluting Balloons Only in Treatment of Coronary Bifurcation Lesion (ROBUST Study)","CompaRison of corOnary BifUrcation Treatment With and Without Stenting Using Only Drug eluTing Balloons (ROBUST Study)","ROBUST","Inclusion Criteria:\n\n* Patients with CCS with documented myocardial ischemia in area supplying by the target coronary artery, not older than 80 years and with an expected life expectancy of at least 1 year\n* Patients with single- or multivessel disease and \"true\" (1.1.1; 1.1.0; and 0.1.1 according to the Medina classification) de novo bifurcation stenosis \\> 50% and \\\u003C100% of the main coronary artery (excluding of the left main) or their large side branches.\n* Both main and side branches should be ≥ 2.0 mm and ≤ 4.5 mm in diameter (according to Quantitative coronary angiography - QCA or intravascular imaging)\n* Length of the main branch lesion should be no more than 30 mm\n* The total length of the side branch should be no more than 7 cm, and the side branch lesion length should be no more than 10 mm\n* Patients without hereditary coagulopathies\n* With a recent (at least 3 months) history of acute coronary syndrome (ACS)\n* Signed informed consent by patient to participate in the study\n\nExclusion Criteria:\n\n* Patients with a single remaining artery supplying a large area of myocardium at risk, regardless of its caliber\n* Over 80 years of age\n* Bifurcation stenosis of the left main coronary artery and bifurcation lesions other than 1.1.1; 1.0.1, and 0.1.1 according to the Medina classification\n* The difference between the proximal and distal reference diameter of the main artery is \\> 1 mm\n* Pregnancy or breastfeeding\n* Severe valvular heart disease requiring surgical or percutaneous intervention within 1 year\n* Life expectancy less than 1 year.\n* Chronic renal failure (glomerular filtration rate less than 30 ml\u002Fmin)\n* Concomitant cancer\n* Heart failure \\> NYHA class II\n* In-stent restenosis in bifurcation lesions after previously performed PCI\n* Presence of thrombus containing Lesion\n* Without concomitant chronic occlusion (bifurcation included in the chronic coronary occlusion (CTO))\n* Patients at high bleeding risk (according to the PRECISE-DAPT score)\n* LV ejection fraction according to echocardiography ≤ 0.4\n* Anemia (Hb \\\u003C 10 g\u002FdL)\n* Thrombocytopenia and any coagulopathy\n* Episodes of significant bleeding and ongoing bleeding requiring modification of medical therapy\n* Acute coronary syndrome\n* PCI or coronary artery bypass grafting (CABG) performed according to clinical indications\n* Patient non-adherence to therapy, including antiplatelet and\u002For anticoagulant medications",{"count":654,"type":22},272,[104],"The goal of this clinical trial is to learn immediate and follow up results of percutaneous treatment of coronary bifurcation lesion using drug eluting balloons (DEB) only in patients with chronic coronary syndrome (CCS). Researchers will compare endovascular treatment using solely DEB to stenting of coronary bifurcation lesion. The main questions it aims to answer are:\n\n* What is immediate and follow up clinical and angiographic results of endovascular treatment of coronary bifurcation lesion using DEB in patients with CCS?\n* Is efficacy and safety of endovascular treatment of coronary bifurcation lesion using DEB only in patients with CCS non inferior to compare stenting of aforementioned lesion which is contemporary recommended standard of care?\n\nParticipants will:\n\n* Take prescribed medication before and after initial procedure during whole observation period (12 months)\n* Visit the clinic at 1, 6 and 12 months after the initial procedure for checkup, noninvasive tests and control angiography at 12 months follow up\n* Inform researchers about all adverse events that might be occur during follow up observation period",[26,213,658,659],"Coronary Stenting","Drug Eluting Balloon",[661,662,663,415],"coronary bifurcation stenting","drug eluting balloon","true coronary bifurcation lesion","2026-04-20",{"date":666,"type":36},"2026-04-27",{"date":668,"type":22},"2026-06-02",{"date":670,"type":22},"2028-02-20",{"name":672,"class":43},"Avtandil M. Babunashvili",{"id":674,"slug":675,"hasResults":12,"nctId":676,"briefTitle":677,"officialTitle":678,"acronym":4,"eligibilityCriteria":679,"healthyVolunteers":53,"sex":18,"minAge":680,"maxAge":4,"enrollmentInfo":681,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":682,"conditions":683,"keywords":689,"overallStatus":160,"whyStopped":4,"lastUpdateSubmitDate":697,"lastUpdatePostDateStruct":698,"startDateStruct":699,"completionDateStruct":700,"leadSponsor":702,"locationsCount":118},"100631593","validation-of-remote-photoplethysmography-rppg-derived-cardiovascular-parameters-against-standard-clinical-measurements-and-risk-scores-in-a-community-100631593","NCT07502703","Validation of Remote Photoplethysmography (rPPG)-Derived Cardiovascular Parameters Against Standard Clinical Measurements and Risk Scores in a Community","Validation of Remote Photoplethysmography (rPPG)-Derived Cardiovascular Parameters Against Standard Clinical Measurements and Risk Scores in a Community-Based Population in Semanan, Jakarta","Inclusion Criteria:\n\n1. Adults aged ≥30 years\n2. Willing to participate and provide informed consent\n3. Able to undergo face scan, clinical examination, and laboratory testing\n\nExclusion Criteria:\n\n1. Facial abnormalities interfering with rPPG signal acquisition\n2. Inability to remain still during measurement\n3. Severe clinical instability\n4. Incomplete key variables","30 Years",{"count":154,"type":22},"The goal of this observational study is to evaluate whether a contactless camera-based technology, called remote photoplethysmography (rPPG), can accurately measure cardiovascular parameters and estimate cardiovascular risk in adults aged 30 years and older living in a community setting in Semanan, Jakarta. This study aims to determine if rPPG can be used as a simple and accessible tool for early cardiovascular screening.\n\nThe main questions it aims to answer are:\n\n1. Do cardiovascular parameters measured using rPPG (such as blood pressure, heart rate, and cardiac workload) agree with standard clinical measurements?\n2. Do cardiovascular risk estimates generated by rPPG (such as ASCVD risk and Framingham heart age) correspond to risk calculations obtained using conventional clinical and laboratory methods?\n\nResearchers will compare results obtained from rPPG-based facial video scans with results from standard medical assessments, including blood pressure measurements, heart rate evaluation, and laboratory tests for cholesterol levels, to determine the level of agreement and accuracy.\n\nParticipants will:\n\n1. Undergo a short facial video scan (approximately 30-60 seconds) using an rPPG-based system\n2. Receive standard clinical assessments, including blood pressure and heart rate measurements\n3. Provide basic health information (such as age, sex, smoking status, and treatment history) Undergo simple laboratory testing for cholesterol levels\n\nThis study is expected to help determine whether rPPG can be used as a reliable, non-invasive, and scalable screening tool for cardiovascular risk in community and primary healthcare settings.",[684,685,26,686,687,688],"Dyslipidemia","Angina (Stable)","Heart Disease","Hypertension","Diabetes (DM)",[690,691,692,693,694,695,696],"remote photoplethysmography","rPPG","cardiovascular risk","ASCVD","Framingham score","digital health","screening tool","2026-04-15",{"date":664,"type":36},{"date":637,"type":22},{"date":701,"type":22},"2026-12-30",{"name":703,"class":43},"Tarumanagara University",{"id":705,"slug":706,"hasResults":12,"nctId":707,"briefTitle":708,"officialTitle":709,"acronym":4,"eligibilityCriteria":710,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":711,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":713,"conditions":714,"keywords":717,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":723,"lastUpdatePostDateStruct":724,"startDateStruct":726,"completionDateStruct":728,"leadSponsor":730,"locationsCount":197},"100633222","multi-omics-based-novel-thrombosis-and-bleeding-markers-and-risk-model-for-chd-100633222","NCT07523880","Multi-Omics-Based Novel Thrombosis and Bleeding Markers and Risk Model for CHD","Multi-Omics-Based Development of Novel Thrombosis and Bleeding Markers and Construction of a Risk Prediction Model in Coronary Heart Disease","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Hospitalized due to symptoms or objective evidence of coronary heart disease and planned for long-term antithrombotic therapy.\n3. Diagnosis of acute coronary syndrome or stable coronary heart disease undergoing percutaneous coronary intervention (PCI), with clinical stability meeting discharge criteria after treatment.\n4. For patients from the existing cohort: minimum 2 years of follow-up with complete clinical data and blood specimens available; approval for use of these data and specimens has been obtained, with a waiver of re-consent.\n\nFor newly enrolled patients: voluntary written informed consent provided by the patient or legal representative, agreement to provide blood samples, and acceptance of follow-up procedures.\n\nExclusion Criteria:\n\nFor patients from the existing cohort:\n\n1. Severe missing or erroneous baseline or clinical data that cannot be corrected by source verification.\n2. No available blood specimen, or specimen that does not meet testing requirements.\n\nFor newly enrolled patients:\n\n1. Presence of serious comorbid conditions with life expectancy ≤ 6 months.\n2. Conditions that significantly affect study compliance or the ability to complete follow-up.\n3. Contraindications to blood sampling.",{"count":712,"type":22},12154,"Patients with coronary heart disease who take dual antiplatelet therapy face two serious risks: thrombosis and major bleeding. This study aims to develop better ways to predict these risks and guide personalized treatment.\n\nThe investigators will use a large, long-term follow-up study of Chinese patients with coronary heart disease. This research plans to discover new biomarkers related to clot and bleeding risk. The study will combine information from proteins, metabolites, sugars attached to proteins, genes, and medical images. Using machine learning methods, the investigators will identify the most important markers and test them in the patient group of this study.\n\nThe investigators will then build new risk prediction models that include these new markers together with traditional risk scores (such as GRACE, PARIS, and Precise-DAPT). This study will check whether these new models are better than existing ones at predicting who will develop clots or bleeding and at helping doctors decide on the best treatment for each patient.\n\nThe new aspects of this research are: (1) using advanced multi-omics technology to find novel markers specifically for Chinese patients; (2) combining clinical, biological, and imaging data to improve prediction accuracy; and (3) using machine learning to create more precise risk models.\n\nThe goal is to provide doctors with a more accurate tool to assess each patient's risk of clots and bleeding. This will help them choose the safest and most effective antiplatelet treatment, reduce serious complications, and improve patient care.",[715,716,26],"Thrombosis","Bleeding",[718,719,715,716,720,540,721,722],"Coronary Heart Disease","Dual Antiplatelet Therapy","Multi-Omics","Risk Prediction Model","Machine Learning","2026-04-06",{"date":725,"type":36},"2026-04-13",{"date":727,"type":36},"2025-08-01",{"date":729,"type":22},"2029-07",{"name":731,"class":43},"Xueyan Zhao"]